IL139832A0 - Therapeutic compositions that produce an immune response by altering the antigen - Google Patents

Therapeutic compositions that produce an immune response by altering the antigen

Info

Publication number
IL139832A0
IL139832A0 IL13983299A IL13983299A IL139832A0 IL 139832 A0 IL139832 A0 IL 139832A0 IL 13983299 A IL13983299 A IL 13983299A IL 13983299 A IL13983299 A IL 13983299A IL 139832 A0 IL139832 A0 IL 139832A0
Authority
IL
Israel
Prior art keywords
altering
antigen
produce
immune response
therapeutic compositions
Prior art date
Application number
IL13983299A
Other languages
English (en)
Original Assignee
Altarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/152,698 external-priority patent/US7361346B1/en
Application filed by Altarex Inc filed Critical Altarex Inc
Publication of IL139832A0 publication Critical patent/IL139832A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13983299A 1998-06-15 1999-06-15 Therapeutic compositions that produce an immune response by altering the antigen IL139832A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9459898A 1998-06-15 1998-06-15
US09/152,698 US7361346B1 (en) 1996-05-15 1998-09-02 Therapeutic compositions that produce an immune response
PCT/IB1999/001114 WO1999065517A2 (en) 1998-06-15 1999-06-15 Therapeutic compositions that produce an immune response by altering the antigen

Publications (1)

Publication Number Publication Date
IL139832A0 true IL139832A0 (en) 2002-02-10

Family

ID=26789062

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13983299A IL139832A0 (en) 1998-06-15 1999-06-15 Therapeutic compositions that produce an immune response by altering the antigen
IL139832A IL139832A (en) 1998-06-15 2000-11-21 Use of binding agents which bind antigens in the preparation of pharmaceutical compositions for inducing an immune response against said antigens and such compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL139832A IL139832A (en) 1998-06-15 2000-11-21 Use of binding agents which bind antigens in the preparation of pharmaceutical compositions for inducing an immune response against said antigens and such compositions

Country Status (6)

Country Link
EP (2) EP1085902A2 (de)
JP (1) JP2002518342A (de)
AU (1) AU762699B2 (de)
CA (1) CA2333221A1 (de)
IL (2) IL139832A0 (de)
WO (1) WO1999065517A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US7361346B1 (en) * 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
IL152747A0 (en) 2000-05-11 2003-06-24 Altarex Inc Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
CA2436233C (en) * 2001-01-30 2010-10-05 Altachem Pharma Ltd. Perylenequinones for use with immunotherapy agents
AU2002324937B2 (en) * 2001-09-07 2008-11-13 The Trustees Of Boston Univeristy Method and composition for treating immune complex associated disorders
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
JP5205264B2 (ja) 2005-08-10 2013-06-05 クウェスト・ファーマテック・インコーポレイテッド ペリレンキノン誘導体及びその使用
US8454991B2 (en) 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
WO2008127285A2 (en) * 2006-10-05 2008-10-23 The Board Of Trustees Of The University Of Arkansas Target peptides for ovarian cancer immunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925362A (en) * 1993-08-11 1999-07-20 Jenner Technologies Method to elicit an antitumor response with human prostate-specific antigen
SI0910407T1 (en) * 1996-05-15 2003-10-31 Altarex Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
CA2292912A1 (en) * 1997-06-17 1998-12-23 Altarex Corp. Therapeutic composition and method of treatment
IL152747A0 (en) * 2000-05-11 2003-06-24 Altarex Inc Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
US20050031619A1 (en) * 2001-03-21 2005-02-10 Nicodemus Christopher F. Therapeutic compositions that alter the immune response

Also Published As

Publication number Publication date
AU762699B2 (en) 2003-07-03
WO1999065517A3 (en) 2000-02-03
JP2002518342A (ja) 2002-06-25
IL139832A (en) 2006-08-20
EP1820514A2 (de) 2007-08-22
CA2333221A1 (en) 1999-12-23
EP1820514A3 (de) 2007-10-17
WO1999065517A2 (en) 1999-12-23
AU4159399A (en) 2000-01-05
EP1085902A2 (de) 2001-03-28

Similar Documents

Publication Publication Date Title
ZA982253B (en) Therapeutic compositions.
ZA984849B (en) Compositions.
ZA200005478B (en) Shampoo compositions.
HUP0101047A3 (en) Combined vaccine compositions
ZA961460B (en) Vaccine compositions
PL352159A1 (en) Pharmaceutical compositions containing antibody against the fas
NO20010873L (no) Mikropartikkel-blanding
GB2364642B (en) Compositions for enhancing the immune response
ID23772A (id) Komposisi-komposisi melalui mulut
GB2390811B (en) Therapeutic compositions that alter the immune response
ZA200105595B (en) Modulation of immune response by Ribavirin.
EP1070121A4 (de) Ef-7, ein mitglied der zytokin-familie.
DE69609897D1 (de) Aromazusammensetzungen mit verzögerter Freigabe
GB9807062D0 (en) Immune response
AU2002355054A1 (en) Human glioma antigen originating in testis
ZA9810275B (en) Therapeutic compositions that produce an immune response.
ZA200103156B (en) Methods of downmodulating the immune response to therapeutic proteins.
GB9825184D0 (en) Antigen
GB9822619D0 (en) Immune response stimulation
GB9915419D0 (en) Antigens
GB0014437D0 (en) Immune response stimulation
GB2334672B (en) The Allenderry chair
AU2002362494A1 (en) Tumor-peptide antigens from the human prdi-bf1-protein
ZA200004975B (en) Adjuvant compositions.
GB0109114D0 (en) Stimulation of the immune system

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed